Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 17.23% ano a ano.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ .
Sobreavaliada
O PE mais recente da empresa é -1.47, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 173.34M ações, uma redução de 27.12% em relação ao trimestre anterior.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.34.